We are monitoring the impact of COVID-19 on Biosimilars Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1078
Share on
Share on

Global Biosimilars Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Product Type, Disease, Application and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1078
Pages: 175

Biosimilars Market Size (2021 to 2026)

As per our research report, the global biosimilars market size was worth USD 6.26 billion in 2021. This figure is forecasted to grow at a remarkable compound annual growth rate (CAGR) of 39.39% and reach USD 32.93 billion by 2026. 

According to WHO, A biosimilar is a biological product similar to the already licensed reference biotherapeutic product similar to quality, safety, and efficacy. It is the same as the generic drug, but it contains a biological entity. According to the FDA, FDA-approved biosimilars have been compared to FDA-approved biosimilars, known as the reference product. Reference and biosimilar products are large and generally complex molecules produced by living organisms that are carefully monitored to ensure consistent quality. Biosimilars are copies of drugs similar to biological drugs that have already been authorized (biological reference medicine) and are similar but not identical. The Indian Guidelines define "similar biologics" as a biological product/drug produced by genetic engineering techniques and claimed to be "similar" in terms of safety, efficacy, and quality to the reference biologics authorized by the Drug Controller General of India (DCGI) for safe use in India. The main reason for the development of biosimilar drugs is the patent protection expiry for many biological medicines.

MARKET DRIVERS:

The cost-effective nature of biosimilars and the increasing prevalence of chronic diseases are major drives of the global biosimilars market growth.

Adalimumab (Humira) for rheumatoid arthritis and trastuzumab (Herceptin) for breast cancer are commonly used biologics. According to WHO, chronic disorders such as Diabetes prevalence have increased faster in low-and middle-income countries than in high-income countries. In 2016, an estimated 1.6 million deaths were directly due to diabetes. Another 2.2 million deaths were due to high blood glucose levels in 2012. Asthma was estimated that more than 339 million people worldwide in 2016. Cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. Cancer Globally causes about 1 in 6 deaths.

Increasing manufacturing by biopharmaceutical companies globally is another significant contribution to the global biosimilars market growth.

Approximately 100 biopharmaceutical companies are actively involved in the research and development, production, and marketing of biosimilar therapeutic products in India. Rising government initiatives and FDA approval are further expected to add fuel to the growth rate of the biosimilars market. The FDA was given the authority to approve biosimilars, including interchangeable ones, to maintain the biosimilar product's safety, efficacy, and quality.

Furthermore, biosimilars regulations are critical for ensuring the viability and balance between original and biosimilar drugs. Factors such as the rising demand for prescription drugs, especially high-priced patented drugs, contribute to the rising demand for pharmaceutical drugs. Many current biological products, such as Erbitux, Avastin, and Orencia, will see their patents expire, providing an opening for many innovator firms and generic vendors to provide services specifically suited to biosimilars. The demand to cut healthcare spending and the patent expiration of numerous blockbuster products, and a growing number of biosimilar drug approvals by the FDA are expected to drive biosimilars market growth. The launch of new biosimilars, strategic innovations by industry players such as alliances and collaborations, favorable research funding situation, and drug development pressure on pharmaceuticals due to impending patent expiry contribute to the market's rise.

MARKET RESTRAINTS:

Patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. The high cost of comparison drugs, on the other hand, limits the market growth by increasing the financial pressure on patients and reimbursement service providers. These high prices are a consequence of a lack of economies of scale owing to reduced demand. Biosimilar costs are not as low as generics due to complex biological production processes for individual biosimilars. The most expensive biologics may cost USD 50,000 a year or more. Biologic drugs are more complex to manufacture than generic drugs. Because it’s not as easy to make a biosimilar drug as it is to make a generic version of a brand-name drug, it is due to most of the drugs are made from chemicals and have a known structure. The aforementioned are some of the factors restraining the growth of the biosimilars market.

Impact of COVID-19 on the global biosimilars market:

The impact of COVID-19 on the Biosimilars market may be significant and has posed a major challenge to pharmaceutical companies focusing on biosimilar development. The reduction in FDA approval of non-COVID therapists during the current pandemic is expected to delay product approvals and launches, hindering the market growth. Also, as most clinical trials have been postponed to combat COVID-19 and minimize infection among participants, most pipeline products show a slow pace of research and development activities.

Also, due to lockdown and travel restrictions across the globe, there is a shortage of supply chains and raw materials that would impact biosimilar production. Thus, due to the aforementioned factors, COVID-19 has a significant impact on the market under study. In the coming decade, there would be an increase in the patent expiry of several existing biological drugs, such as Erbitux, Avastin, Orencia, and others, which would provide an opportunity for many innovative companies and generic manufacturers to offer services tailored specifically to biosimilars. Also, factors such as the cost-effective nature of biosimilars, increasing acceptance and acceptance by various stakeholders in need of diversification of technology and business models, the growing prevalence of chronic diseases is expected to drive the global biosimilars market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Product Type, Technology, Disease & Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

The global biosimilars market research report has been segmented and sub-segmented into the product type, technology, disease, and end-user.

Biosimilars Market - By Product Type:

  • Protein
  • Insulin
  • Human Growth Hormones
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon

The Recombinant non-glycosylated protein product type holds a significant share of the global biosimilars market based on the product type. Globally, an increase in the development rate of insulin and growth hormone products is boosting the market growth. The market for biosimilars is expected to grow in response to rising cancer incidences. During the forecast period, the Recombinant Glycosylated Protein segment is expected to grow at a fast rate. Biological drugs such as erythropoietin and monoclonal antibodies are predicted to develop this category over this period due to patent expiration.

Biosimilars Market - By Technology:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic resonance (NMR) technology
  • Electrophoresis
  • Bioassay

Based on Technology, recombinant DNA technology is the most lucrative segment among all and estimated to register a healthy growth rate during the forecast period and is responsible for developing biosimilar drugs such as human growth hormones, insulin, and erythropoietin. The bio-ability similar to cure diseases quickly and effectively is enhanced by advanced technology.

During the projected period, monoclonal antibody technology is expected to rise at a 30.0 percent CAGR. The number of monoclonal antibody uses for cancer and autoimmune disorders have resulted in monoclonal antibody technology's rapid development, propelling the market forward.

Biosimilars Market - By Disease:

  • Oncology Diseases
  • Blood Disorders
  • Growth hormone deficiencies
  • Chronic and autoimmune diseases
  • Others

Based on the disease, oncology disease dominated the market. Owing to the increased availability of lower-cost biosimilar drugs to treat cancer, the Oncology market leads with the largest share of the global biosimilars market. Factors such as drug clearance for various categories of medications, this section is leading. One of the major factors driving the growth of this oncology disease sector is the many oncology drugs available in the cancer care market.

On the other hand, a blood disorder is anticipated to witness significant growth during the forecast period. With delivering earnings, the blood disorders segment is likely to develop. Common diseases such as anemia and hemophilia and promising outcomes from ongoing clinical trials are some of the factors driving the market growth.

Biosimilars Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

In 2020, North America held the largest share in the global biosimilars market. It is due to the acceptance of the advanced technologies coming into the market in this region. The introduction of various drugs and products that receive approval from the FDA is expanding the market growth in this region.

Europe region is followed by North America that is influencing the market growth during the period due to the increase in constructional activities on healthcare centers for providing proper care for the patient.

The Asia-Pacific market has the quickest region during recent years and also in the upcoming years. The area is to hit the industry with a CAGR value during the period. The growing annual income of a person per annum in developing countries is accelerating the growth of the biosimilars market.

The Middle East & Africa has to continue their growth rate during the forecast period.

KEY MARKET PARTICIPANTS:

Some of the promising companies dominating the global biosimilars market profiled in the report are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics, and Cipla Ltd. Global industry players are engaging in corporate investments, partnerships, and mergers to maintain their market positions.

RECENT MARKET DEVELOPMENTS:

  • The FDA approved Fujifilm Kyowa Kirin Biologics' adalimumab biosimilar Hulio in July 2020 for the subcutaneous treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
  • In April 2020, Pfizer planned to launch two additional biosimilars in the United States. Their commitment to the development of biosimilars is extraordinary amid the COVID-19 pandemic, where the focus has turned to Coronavirus medicine and vaccine development.
  • The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) both approved Fresenius Kabi's regulatory submissions for its proposed pegfilgrastim biosimilar (MSB11455) in May 2020.

1.Introduction                                   

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 South Korea           

                                6.3.6 Australia  

                6.4 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Argentina

                                6.4.4 Mexico     

                6.5 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa        

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Biosimilars Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  3. Global Protein Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Insulin Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Interferons Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  15. Global Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  16. Global Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  18. Global Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Million)
  19. Global Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  20. Global Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  21. Global Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  22. Global Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  23. Global Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  24. Global Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  25. Global Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  26. Global Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  27. Global Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  28. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  30. North America Protein Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Insulin Market, By Region, From 2021 to 2026 (USD Million)
  32. North America Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  34. North America Interferons Market, By Region, From 2021 to 2026 (USD Million)
  35. North America Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  36. North America Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  37. North America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  38. North America Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  39. North America Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  40. North America Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  41. North America Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  42. North America Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  43. North America Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  44. North America Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  45. North America Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Million)
  46. North America Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  47. North America Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  48. North America Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  49. North America Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  50. North America Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  51. North America Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  52. North America Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  53. North America Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  54. North America Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  55. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  56. United States Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  57. United States Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  58. United States Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  59. Canada Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  60. Canada Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  61. Canada Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  62. Europe Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  63. Europe Protein Market, By Region, From 2021 to 2026 (USD Million)
  64. Europe Insulin Market, By Region, From 2021 to 2026 (USD Million)
  65. Europe Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  66. Europe Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  67. Europe Interferons Market, By Region, From 2021 to 2026 (USD Million)
  68. Europe Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  69. Europe Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  70. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  71. Europe Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  72. Europe Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  73. Europe Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  74. Europe Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  75. Europe Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  76. Europe Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  77. Europe Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  78. Europe Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Million)
  79. Europe Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  80. Europe Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  81. Europe Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  82. Europe Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  83. Europe Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  84. Europe Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  85. Europe Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  86. Europe Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  87. Europe Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  88. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  89. U.K. Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  90. U.K. Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  91. U.K. Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  92. Germany Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  93. Germany Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  94. Germany Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  95. France Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  96. France Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  97. France Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  98. Italy Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  99. Italy Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  100. Italy Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  101. Spain Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  102. Spain Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  103. Spain Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  104. Asia-Pacific Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  105. Asia-Pacific Protein Market, By Region, From 2021 to 2026 (USD Million)
  106. Asia-Pacific Insulin Market, By Region, From 2021 to 2026 (USD Million)
  107. Asia-Pacific Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  108. Asia-Pacific Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  109. Asia-Pacific Interferons Market, By Region, From 2021 to 2026 (USD Million)
  110. Asia-Pacific Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  111. Asia-Pacific Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  112. Asia-Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  113. Asia-Pacific Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  114. Asia-Pacific Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  115. Asia-Pacific Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  116. Asia-Pacific Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  117. Asia-Pacific Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  118. Asia-Pacific Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  119. Asia-Pacific Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  120. Asia-Pacific Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Million)
  121. Asia-Pacific Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  122. Asia-Pacific Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  123. Asia-Pacific Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  124. Asia-Pacific Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  125. Asia-Pacific Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  126. Asia-Pacific Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  127. Asia-Pacific Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  128. Asia-Pacific Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  129. Asia-Pacific Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  130. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  131. Japan Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  132. Japan Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  133. Japan Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  134. China Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  135. China Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  136. China Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  137. India Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  138. India Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  139. India Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  140. Latin America Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  141. Latin America Protein Market, By Region, From 2021 to 2026 (USD Million)
  142. Latin America Insulin Market, By Region, From 2021 to 2026 (USD Million)
  143. Latin America Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  144. Latin America Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  145. Latin America Interferons Market, By Region, From 2021 to 2026 (USD Million)
  146. Latin America Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  147. Latin America Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  148. Latin America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  149. Latin America Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  150. Latin America Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  151. Latin America Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  152. Latin America Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  153. Latin America Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  154. Latin America Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  155. Latin America Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  156. Latin America Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Million)
  157. Latin America Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  158. Latin America Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  159. Latin America Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  160. Latin America Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  161. Latin America Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  162. Latin America Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  163. Latin America Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  164. Latin America Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  165. Latin America Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  166. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  167. Brazil Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  168. Brazil Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  169. Brazil Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  170. Rest of Latin America Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  171. Rest of Latin America Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  172. Rest of Latin America Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  173. Middle East & Africa Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  174. Middle East & Africa Protein Market, By Region, From 2021 to 2026 (USD Million)
  175. Middle East & Africa Insulin Market, By Region, From 2021 to 2026 (USD Million)
  176. Middle East & Africa Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Million)
  177. Middle East & Africa Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Million)
  178. Middle East & Africa Interferons Market, By Region, From 2021 to 2026 (USD Million)
  179. Middle East & Africa Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Million)
  180. Middle East & Africa Erythropoietin Market, By Region, From 2021 to 2026 (USD Million)
  181. Middle East & Africa Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  182. Middle East & Africa Follitropin Market, By Region, From 2021 to 2026 (USD Million)
  183. Middle East & Africa Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Million)
  184. Middle East & Africa Glucagon Market, By Region, From 2021 to 2026 (USD Million)
  185. Middle East & Africa Calcitonin Market, By Region, From 2021 to 2026 (USD Million)
  186. Middle East & Africa Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  187. Middle East & Africa Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Million)
  188. Middle East & Africa Chromatography Market, By Region, From 2021 to 2026 (USD Million)
  189. Middle East & Africa Monoclonal Antibody Technology Market, By Region, From 2020 - 2025 (USD Million)
  190. Middle East & Africa Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Million)
  191. Middle East & Africa Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Million)
  192. Middle East & Africa Electrophoresis Market, By Region, From 2021 to 2026 (USD Million)
  193. Middle East & Africa Bioassay Market, By Region, From 2021 to 2026 (USD Million)
  194. Middle East & Africa Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  195. Middle East & Africa Oncology diseases Market, By Region, From 2021 to 2026 (USD Million)
  196. Middle East & Africa Blood disorders Market, By Region, From 2021 to 2026 (USD Million)
  197. Middle East & Africa Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Million)
  198. Middle East & Africa Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Million)
  199. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  200. Middle East Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  201. Middle East Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  202. Middle East Biosimilars Market, By Application, From 2021 to 2026 (USD Million)
  203. Africa Biosimilars Market, By Type, From 2021 to 2026 (USD Million)
  204. Africa Biosimilars Market, By Technology, From 2021 to 2026 (USD Million)
  205. Africa Biosimilars Market, By Application, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample